KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Patil, Harshali ^a   Korde, Rajesh ^a   Kapat, Arnab ^a  

^a RELIANCE LIFE SCIENCES PVT LTD   (India)

Author keywords

Colorectal cancer; Indian patients; KRAS; Mutations

Indexed keywords

BIOLOGICAL MARKER; DNA; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; DNA EXTRACTION; EXON; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HUMAN; INDIAN; KRAS GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION; WESTERN HEMISPHERE; AGED; CELL DIFFERENTIATION; COLORECTAL TUMOR; FEMALE; GENETICS; INDIA; MUTATION; ONCOGENE RAS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; INDIA; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; YOUNG ADULT;

EID: 84878244603     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0617-5     Document Type: Article

References (22)

1. Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
2. Yeole BB, et al. Population-based survival from colorectal cancer in Mumbai, (Bombay) India. Eur J Cancer. 2001;37(11):1402-8.
3. Velho S. et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? Bmc Cancer. 2008;8.
4. Karapetis CS, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-65.
5. Bagadi SB, et al. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers. 2012;27(1):27-33.
6. Javid G, et al. Incidence of colorectal cancer in Kashmir valley, India. Indian J Gastroenterol. 2011;30(1):7-11.
7. Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytömaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. J Clin Pathol Mol Pathol. 2000;53:24-30.
8. Arrington AK, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012;13(10):12153-68.
9. Valtorta E, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. International Journal of Cancer. 2013. doi:10.1002/ijc.28106.
10. Ozen F, et al. The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. Genet Test Mol Biomarkers. 2013;17(2):135-9.
11. Mao C, et al. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. Plos One. 2012; 7(5).
12. Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, Claes B, De Hertogh G, Van Cutsem E, Tejpar S KULeuven, Leuven, Belgium; University Hospital Gasthuisberg, KULeuven, Leuven, Belgium, The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. Journal of Clinical Oncology. 2009;27(15 s).
13. Fransen K, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25(4):527-33.
14. Conlin A, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283-6.
15. Vaughn CP, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer. 2011;50(5): 307-12.
16. Neumann J, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205(12):858-62.
17. Velho S, Oliveira C, Seruca R. KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. J Clin Oncol. 2009;27(1):158-9.
18. Sameer AS, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15(4):244-52.
19. Farina-Sarasqueta A, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396-402.
20. Gao J, et al. Wild-type KRAS and BRAF could predict response to cetuximab in Chinese colorectal cancer patients. Chin J Cancer Res. 2011;23(4):271-5.
21. Zhu XL, et al. KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese. Zhonghua Bing Li Xue Za Zhi. 2012;41(9):584-9.
22. Rosty C, Young J, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR, Buchanan DD Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathology. 2013.